AMPH Q4 2017 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMPHAmphastar Pharmaceuticals, Inc.

$860M

Q4 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$60M-4.9% YoY

Gross Profit

$21M34.1% margin

Operating Income

-$2M-2.8% margin

Net Income

$1M2.4% margin

EPS (Diluted)

$0.03

QoQ Revenue Growth

+4.3%

Cash Flow

Operating Cash Flow

$10M

Free Cash Flow

-$353,000

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$455M

Total Liabilities

$117M

Stockholders' Equity

$337M

Cash & Equivalents

$66M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$60M	$64M	-4.9%
Gross Profit	$21M	$20M	+3.1%
Operating Income	-$2M	-$5M	+63.1%
Net Income	$1M	-$3M	+153.5%

Revenue Segments

Active Pharmaceutical Ingredient Segment

$4M100%

Geographic Segments

U

$59M100%